Stockchase Opinions

David Burrows Genentech DNA-N BUY Jul 13, 2005

The biotech sector is one of the first growth oriented groups that turned up and has been relatively strong all year. Likes this one because it has a diversified revenue line. Growing cash flow.
$86.650

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

TOP PICK
Growing revenue profits annually 25%. Good products. Good value at this price.
DON'T BUY
Model price is $25.24. Very expensive.
DON'T BUY
One of the largest bio-tech firms in the world. He thinks there is not enough control, in knowing how research is going to be able to proceed. (phase 1 through phase 6). Instead he uses PBE-A which is a portfolio. Less exciting but more rewarding long term.
DON'T BUY
The model price is $48.70, a negative 35% differential. Would choose Amgen (AMGN-Q), which he owns.
HOLD
Once a takeover bid comes in, it no longer trades on fundamentals. If you already own, keep the stock and wait to see what happens. You could take a bit of profit here.